Trials / Completed
CompletedNCT02831686
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of a combination of study drugs called selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone. This study tests different doses of the study drug, selinexor to see which dose is safer in people. Depending on which group (dose level) you are in, the dose of selinexor will vary, but the ixazomib and dexamethasone doses will be the same among the groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | |
| DRUG | Ixazomib | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2020-11-19
- Completion
- 2020-11-19
- First posted
- 2016-07-13
- Last updated
- 2020-11-24
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02831686. Inclusion in this directory is not an endorsement.